Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on Jan 08, 2021 3:03pm
146 Views
Post# 32255930

RE:Thoughts on the PR construction

RE:Thoughts on the PR construction

You have a point.

A stand alone PR and CC for NASH would be merited. They (a) got the nod for Ph3 and (b) announced some wrinkles need ironing out. Somehow the RBC guy downplayed a) and focused on b). Maybe a CC emphasizing that a) was the real big news here would have helped as would a chance to ask questions about the wrinkles.

What did the 3 analysts say about the sales numbers in their reports? If they were more positive about that then maybe the company understand this is the analysts pre-occupation and include it for that reason. I do think it doesn't help to move the discussion over to the R&D though.


SPCEO1 wrote: Yesterday we hit the trifecta - three pieces of unambiguously good news which all enhanced the credibility of management as Palinc has pointed out. So, the focus should be on that good news and we should all be in a good mood as a result as Realitycheck4u admonsihed us to be.

But I do want to enter one criticism into the record.

There was one PR for three big events. Would three PR's in qucik succession have been a better strategy? If not, should not the one PR have led off with the NASH news instead of the far less significant revenue beat? I saw any number of headlines yesterday about TH that only included the news about revenues being at a record level. If you are trying to get your message out, you need to understand how the robots are going to communicate it and adjust accordingly.

OK - I am now going back to being happy. 



 

<< Previous
Bullboard Posts
Next >>